Quinazoline Marketed drugs
Abstract
Quinazoline is the main six-membered heterocyclic ring system reported for their biological activities, compounds with multiple pharmacophores, which bring together knowledge of a target with understanding of the molecule types that might interact with the target family. Robust, versatile and scalable chemistry must be employed to accomplish the task. This characteristic feature of quinazoline would make a good template for a lead generation library. The current review article focuses on biological actions done for various targets along with the brief description of the targets.Downloads
References
Amer, M.S., and Browder, H.P. 1971. Effect of quazodine on phosphodiesterase. Proc Soc Exp
Biol Med. 136(3), 750-752.
Belz, G.G., Stern, H.C., Butzer, R. 1985. Dose-response following single administrations of a new
cardiac performance enhancer RO 13-6438 in normal volunteers. J. Cardiovas. Pharmacol. 7
(1), 86-90.
Chen, K., Wang, K., and Kirichian, A.M. 2006. In silico design, synthesis, and biological
evaluation of radioiodinated quinazolinone derivatives for alkaline phosphatasemediated
cancer diagnosis and therapy. Mol. Cancer Ther. 5 (12), 3001-13.
Cheng, C.M., Lee, Y.J., Wang, W.T., Hsu, C.T., Tsai, J.S., Wu, C.M., Ou, K.L., and Yang, T.S.
Biochem Biophys Res Commun., 404(1), 297-301.
Cohen, E., Klarberg, B., and Vaughan, J.R. (1960). J. Am. Chem.Soci. 82, 2731.
Daly, P.A., Chatterjee, K., and Viquerat, C.E., 1985. RO13-6438, a new inotrope-vasodilator:
systemic and coronary hemodynamic effects in congestive heart failure. Am. J. Cardio. 55,
-44.
Denis, D., and Riendeau, D. 1999. Phosphodiesterase 4-dependent regulation of cyclic AMP
levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes". Euro. J.
Pharmacol. 367, 343-50.
Doods, H., Hallermayer, G., Wu, D., Entzeroth, M., Rudolf, K., Engel, W. and Eberlein,
W. 2000. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP
antagonist. Br J Pharmacol. 129, 420-423.
T Panneer Selvam & P Vijayaraj Kumar / Research in Pharmacy 1(1) : 1-21, 2011
Eigenmann, R., Gerold, M., and Holck, M. 1984. Cardiovascular profile of Ro 13-6438, a novel
positive inotropic agent with vasodilating properties. J. Cardiovas. Pharmacol. 6 (3), 511-9.
Holck, M., Thorens, S., Muggli, R., and Eigenmann, R. 1984. Studies on the mechanism of
positive inotropic activity of Ro 13-6438, a structurally novel cardiotonic agent with
vasodilating properties. J. Cardiovas. Pharmacol. 6 (3), 520-30.
Hughes, A.N., Rafi, I., and Griffin, M.J. 1999. Phase I studies with the nonclassical antifolate
nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. Clin.
Cancer Res. 5 (1), 111-8.
Hwang, D.F., and Noguchi T. 2007. Tetrodotoxin poisoning. Adv. Food Nutr.Res. 52, 141-236.
Ishikawa, T., Kamide, R., and Niimura, M. 1994 Photoleukomelanodermatitis (Kobori) induced
by afloqualone. J. Dermatology. 21(6), 430-3.
Kobayashi, Y. 2001. Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia
rutaecarpa, a vanilloid receptor agonist. In: Planta Med. 67(7), 628-33.
Mallee, J. J., Salvatore, C. A., LeBourdelles, B., Oliver, K. R., Longmore, J., Koblan, K. S. and
Kane, S. A. 2002. Receptor activity-modifying protein 1 determines the species selectivity
of non-peptide CGRP receptor antagonists. J. Biol. Chem. 277, 14294-14298.
McLaughlin, Noel, P., and Evans, P. 2010. Dihydroxylation of Vinyl Sulfones: Stereoselective
Synthesis of (+)- and (−)-Febrifugine and Halofuginone. J. Org. Chem. 75 (2), 518.
Ochiai, T., and Ishida, R. 1982. Pharmacological studies on 6-amino- 2-fluoromethyl- 3-(O-tolyl)-
(3H)- quinazolinone (afloqualone), a new centrally acting muscle relaxant. (II) Effects on
the spinal reflex potential and the rigidity. Japanese J. Pharmacol. 32(3), 427-38.
Osinski, M.T., and Schrör, K. 2000. Inhibition of platelet-derived growth factor-induced
mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular
smooth muscle cell mitogenesis. Bio.chem. Pharmacol. 60 (3), 381-7.
Pao. W., Mille,r V., and Zakowski, M. 2004. EGF receptor gene mutations are common in lung
cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proceedings of the National Academy of Sciences of the United States of America.,
(36), 13306-11.
Petrides, P.E. 2006. Anagrelide: what was new in 2004 and 2005?. Semin. Thromb. Hemost. 32,
-408.
Raymond, E., Faivre, S., Armand, J. 2000. Epidermal growth factor receptor tyrosine kinase as a
target for anticancer therapy. Drugs 60 Suppl 1, 15-23.
Rivera, V.R., Poli, M.A., and Bignami G.S. 1995 Prophylaxis and treatment with a monoclonal
antibody of tetrodotoxin poisoning in mice. Toxicon. 33(9), 1231-7.
Shen, H. 2008. Illustrated Pharmacology Memory Cards: PharMnemonics. Minireview., 13.
Smith, H.O., Blessing, J.A., and Vaccarello, L. 2002. Trimetrexate in the treatment of recurrent or
advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology
Group. Gynecol. Oncol. 84 (1),140-4.
.